InfuSystem Holdings (INFU) AI Stock Analysis

• Market Cap: $193.23M
• Dividend Yield: N/A
• Average Volume (3M): 198.17K
• Price to Earnings (P/E): 39.9
• Beta (1Y): 1.70
• Revenue Growth: 6.23%
• EPS Growth: 283.88%
• Country: US
• Employees: 502
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.11
• Shares Outstanding: 20,425,964
• 10 Day Avg. Volume: 165,826
• 30 Day Avg. Volume: 198,169
• PEG Ratio: 0.46
• Price to Book (P/B): 3.12
• Price to Sales (P/S): 1.33
• P/FCF Ratio: 68.45
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $14.50
• Price Target Upside: 51.04% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 68 Neutral
• Price Target: $10.50 ▲(9.38% Upside)

InfuSystem Holdings shows strong financial performance with significant revenue growth and strategic initiatives in Oncology and Wound Care. However, the stock is currently overvalued, and challenges in certain revenue streams pose risks. Technical indicators suggest mixed momentum, with short-term bearish signals but longer-term positive trends.

Positive Factors

Revenue Growth

Consistent revenue growth indicates robust market demand and effective business strategies, enhancing long-term financial stability.

Strategic Initiatives

Strategic initiatives in Oncology and contract wins strengthen market position and provide a foundation for sustained growth.

Debt Reduction

Reducing debt enhances financial flexibility and reduces interest expenses, supporting long-term financial health.

Negative Factors

Biomedical Services Revenue Decline

The decline in biomedical services revenue could impact overall revenue growth, posing a risk to financial performance.

Device Solutions Revenue Decrease

Decreasing revenue in Device Solutions suggests challenges in maintaining product demand, affecting future revenue streams.

Free Cash Flow Growth

Negative free cash flow growth may limit the company's ability to invest in growth opportunities and manage financial obligations.

InfuSystem Holdings Business Overview & Revenue Model

Company Description

InfuSystem Holdings, Inc. (INFU) is a leading provider of infusion pumps and related services, primarily serving the healthcare sector. The company specializes in the rental and sale of infusion pumps, as well as providing a comprehensive suite of services, including maintenance, logistics, and patient support. InfuSystem's core products cater to various medical applications, including pain management, chemotherapy, and antibiotic therapies, making it an essential partner for hospitals, clinics, and home healthcare providers.

How the Company Makes Money

InfuSystem generates revenue through multiple key streams, primarily from the rental and sale of infusion pumps and related equipment. The company charges healthcare facilities for the leasing of their infusion devices, which can include both short-term and long-term contracts. Additionally, InfuSystem earns income through the provision of consumables, such as IV administration sets and related supplies necessary for the operation of their infusion systems. Service agreements, which encompass maintenance, repair, and technical support, also contribute significantly to the company's revenue. Strategic partnerships with healthcare providers and manufacturers further enhance their market reach and service offerings, allowing InfuSystem to secure recurring revenue and build long-term customer relationships.

InfuSystem Holdings Financial Statement Overview

Summary

InfuSystem Holdings demonstrates strong revenue growth and improved leverage, positioning it well for future expansion. However, profitability margins and free cash flow growth present areas for improvement to ensure sustainable financial health.

Income Statement

InfuSystem Holdings shows a strong revenue growth rate of 83.5% in TTM, indicating robust expansion. Gross profit margin improved to 55.35%, reflecting efficient cost management. However, the net profit margin remains modest at 3.92%, suggesting room for profitability enhancement.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.45, indicating a reduction in leverage and a stronger equity position. Return on equity is at 9.92%, showing a decent return on shareholders' investments. The equity ratio is stable, suggesting a balanced asset structure.

Cash Flow

Operating cash flow is strong with a coverage ratio of 1.35, indicating good cash generation relative to net income. However, free cash flow growth is negative at -6.58%, pointing to potential challenges in maintaining cash reserves.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	141.05M	134.86M	125.78M	109.91M	102.38M	97.39M
Gross Profit	78.08M	70.40M	63.11M	60.56M	58.54M	58.76M
EBITDA	14.89M	20.03M	16.53M	14.89M	17.26M	22.82M
Net Income	5.52M	2.35M	872.00K	18.00K	1.42M	17.33M
Balance Sheet
Total Assets	98.88M	103.61M	102.92M	99.39M	97.59M	96.99M
Cash, Cash Equivalents and Short-Term Investments	955.00K	527.00K	231.00K	165.00K	186.00K	9.65M
Total Debt	24.69M	28.42M	34.90M	36.92M	36.77M	42.66M
Total Liabilities	43.41M	46.09M	50.61M	51.38M	49.31M	56.24M
Stockholders Equity	55.47M	57.53M	52.30M	48.00M	48.27M	40.75M
Cash Flow
Free Cash Flow	18.65M	2.63M	106.00K	2.44M	1.66M	3.37M
Operating Cash Flow	25.21M	20.46M	11.22M	17.52M	18.32M	20.28M
Investing Cash Flow	-7.87M	-13.24M	-6.73M	-11.48M	-21.32M	-12.16M
Financing Cash Flow	-16.77M	-6.92M	-4.42M	-6.06M	-6.46M	-1.12M

InfuSystem Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INFU, the sentiment is Positive. The current price of 9.6 is below the 20-day moving average (MA) of 9.88, below the 50-day MA of 10.04, and above the 200-day MA of 7.40, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 51.73 is Neutral, neither overbought nor oversold. The STOCH value of 66.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INFU.

InfuSystem Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INFU	68 Neutral	$193.23M	39.88	9.95%	―	6.23%	283.88%
UTMD	63 Neutral	$184.01M	16.24	9.59%	2.09%	-12.35%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SMTI	51 Neutral	$246.73M	―	-25.78%	―	34.29%	-49.21%
KRMD	50 Neutral	$178.47M	-39.27	-25.63%	―	19.57%	61.81%
OSUR	44 Neutral	$171.80M	―	-15.30%	―	-43.95%	-620.21%

InfuSystem Holdings Corporate Events

InfuSystem Holdings Reports Strong Q3 2025 Results

InfuSystem Holdings, Inc. is a national healthcare service provider that facilitates outpatient care for durable medical equipment manufacturers and healthcare providers. The company operates through two main platforms: Patient Services and Device Solutions, offering a range of services including oncology, pain management, and wound therapy.

InfuSystem Holdings Reports Strong Q3 Earnings Amid Challenges

InfuSystem Holdings, Inc. recently held its earnings call, presenting a balanced view of its financial performance. The company showcased strong results in Oncology and Wound Care, but faced challenges with declining revenues in biomedical services and Device Solutions. Despite these setbacks, InfuSystem’s commitment to profitability and operational efficiency was evident.

InfuSystem Holdings to Announce Q3 2025 Results

InfuSystem Holdings, Inc. announced that it will release its third-quarter 2025 financial results on November 4, 2025, before the market opens. The company will also hold a conference call on the same day to discuss the financial results, providing stakeholders with insights into its performance and future outlook.

The most recent analyst rating on (INFU) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on InfuSystem Holdings stock, see the INFU Stock Forecast page.

InfuSystem Holdings Reports Strong 2024 Revenue Growth

InfuSystem Holdings has reported six consecutive years of record revenue, with a compound annual growth rate (CAGR) of 12% in revenue and 11% in adjusted EBITDA. The company generated $134.9 million in total revenue for 2024, with a strong focus on expanding its device solutions and patient services segments. InfuSystem’s strategic partnerships and acquisitions, such as the agreements with Solo-Dex Inc. and Sanara MedTech, highlight its efforts to enhance its market positioning and offer comprehensive solutions in the medical equipment industry. These initiatives are expected to support the company’s growth and provide substantial cash flow, with $20.5 million in cash flow from operations reported for 2024.

The most recent analyst rating on (INFU) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on InfuSystem Holdings stock, see the INFU Stock Forecast page.

InfuSystem Holdings to Join ROTH Healthcare Conference

On September 25, 2025, InfuSystem Holdings, Inc. announced that its CEO, Carrie Lachance, and CFO, Barry Steele, will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, in New York City. This participation is expected to enhance the company’s visibility and investor engagement, potentially impacting its market positioning and stakeholder relations positively.

The most recent analyst rating on (INFU) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on InfuSystem Holdings stock, see the INFU Stock Forecast page.

InfuSystem Holdings Reports Strong Q2 2025 Results

InfuSystem Holdings, Inc. is a national healthcare service provider that facilitates outpatient care for durable medical equipment manufacturers and healthcare providers, operating primarily in the Patient Services and Device Solutions sectors. In its second quarter of 2025, InfuSystem reported record net revenues of $36.0 million, marking a 7% growth from the previous year, alongside a significant increase in net income by 262% to $2.6 million. The company also achieved an adjusted EBITDA of $8.0 million, reflecting a 32% rise, and expanded its EBITDA margin to 22.3%. Key financial highlights include a 6% increase in Patient Services revenue and an 8% rise in Device Solutions revenue, driven by strategic investments and operational efficiencies. The company also repurchased $3.5 million in stock, enhancing shareholder value. Looking ahead, InfuSystem is focusing on expanding margins and improving profitability, with an updated revenue growth outlook of 6-8% for 2025, while aiming for an adjusted EBITDA margin of 20% or higher. The company remains committed to disciplined execution and long-term value creation for its shareholders.

InfuSystem Holdings Reports Mixed Earnings Call Results

InfuSystem Holdings, Inc. recently held its earnings call, revealing a mixed sentiment. The company reported a strong financial performance with record revenue and margin expansion, yet faced challenges such as a reduced revenue growth outlook and uncertainties in specific business areas. Notably, the focus on operational efficiency and shareholder returns were highlighted as positive aspects.